• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Euro Surveill. Extent and origin of resistance to antituberculosis drugs in the Netherlands, 1993 to 2011

Giuseppe

Emeritus
[Source: Eurosurveillance, full page: (LINK). Abstract, edited.]


Eurosurveillance, Volume 19, Issue 11, 20 March 2014 / Research articles

Extent and origin of resistance to antituberculosis drugs in the Netherlands, 1993 to 2011

C Ruesen <SUP>1</SUP>, A B van Gageldonk-Lafeber<SUP>1</SUP>, G de Vries<SUP>1</SUP><SUP>,2</SUP>, C G Erkens<SUP>2</SUP>, J van Rest<SUP>1</SUP><SUP>,2</SUP>, H Korthals Altes<SUP>1</SUP>, H de Neeling<SUP>3</SUP>, M Kamst<SUP>3</SUP>, D van Soolingen<SUP>3</SUP>
<SUP></SUP>
<SUP>1</SUP>Epidemiology and Surveillance, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands - 2 KNCV Tuberculosis Foundation, The Hague, the Netherlands - 3 National Mycobacteria Reference Laboratory, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
______

Citation style for this article: Ruesen C, van Gageldonk-Lafeber AB, de Vries G, Erkens CG, van Rest J, Korthals Altes H, de Neeling H, Kamst M, van Soolingen D. Extent and origin of resistance to antituberculosis drugs in the Netherlands, 1993 to 2011. Euro Surveill. 2014;19(11):pii=20738. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20738
Date of submission: 28 January 2013

______

The elimination of tuberculosis (TB) is threatened by an apparent increase in the level of resistance in Mycobacterium tuberculosis. In the Netherlands, where the majority of TB patients are migrants, resistance may also be increasing. We conducted a retrospective study, using 18,294 M. tuberculosis isolates from TB cases notified between 1993 and 2011. We investigated the trends in antituberculosis drug resistance, focusing on the country of birth of the patients and whether resistance had developed during treatment or was the result of transmission of resistant M. tuberculosis strains. For both scenarios, we determined whether this had happened in or outside the Netherlands. Antituberculosis drug resistance was found in 13% of all cases analysed and showed an increasing trend among patients who had been born in the Netherlands (p<0.001) and a decreasing trend among foreign-born (p=0.02) over the study period. Since 2005, the proportion of M. tuberculosis resistant strains among all strains tested has increased in both groups (p=0.03 and p=0.01, respectively). Overall, we found a significantly increasing trend when excluding streptomycin resistance (p<0.001). The trend was most markedly increased for isoniazid resistance (p=0.01). Although resistance was mainly due to transmission of resistant strains, mostly outside the Netherlands or before 1993 (when DNA fingerprinting was not systematically performed), in some cases (n=45), resistance was acquired in the Netherlands. We conclude that antituberculosis drug resistance is increasing in the Netherlands, mostly related to migration from high TB-incidence countries, but also to domestic acquisition.


-
--------
 
Back
Top Bottom